Fresh analysis reveals that people who discontinue new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who end conventional diet and exercise programs.
Published data in a major medical journal demonstrates that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Users using such treatments need to be aware of the risk of fast rebound weight gain when the therapy ends," warns expert Dr. Susan Jebb.
This pace of recovery suggests a return to original mass in about a year and a half.
Weighing Treatments
The analysis, which examined dozens of studies involving thousands of participants, contrasted the results of these new drugs with older methods.
Scientists note that individuals who lose weight through dieting usually see a slower creep back—around 100 grams monthly—post-intervention.
Understanding the Quick Regain
Experts suggest the way of the injections explains the accelerated rebound.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the system to produce less of its endogenous hormone, and may also diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication results in appetite is uncontrolled, making excessive eating far more likely."
A Chronic Issue?
The NHS suggest the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
A number of clinicians say that, given the likelihood of weight regain, the treatment might need to be life-long.
This view is reinforced by pharmaceutical companies, who note that the results "highlight the chronic nature of obesity," akin to managing conditions like diabetes.
Patient Accounts
Users who have stopped the jabs describe a sudden resurgence of appetite.
"I experienced a trigger flipping and I was suddenly ravenous," described a patient.
This difficulty is exacerbated if patients have not developed sustainable dietary or behavioural changes during treatment.
Widespread Use
Recent estimates indicate that a significant number of people in the UK have tried these injections in the past year, with desire being substantial.
- Use is more common among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, researchers caution that while the jabs are powerful agents for shedding pounds, they are not a magic cure and lasting health benefits hinges on combined lifestyle support.
